334 results on '"Branagan, A. R."'
Search Results
2. Elotuzumab in combination with pomalidomide, bortezomib, and dexamethasone in relapsed and refractory multiple myeloma
3. Ibrutinib and venetoclax as primary therapy in symptomatic, treatment-naïve Waldenström macroglobulinemia
4. Report of consensus panel 1 from the 11th International Workshop on Waldenstrom's Macroglobulinemia on management of symptomatic, treatment-naïve patients
5. Quality of life, psychological distress, and prognostic perceptions in caregivers of patients with multiple myeloma
6. SOHO State of the Art Updates and Next Questions: Targeted therapies and emerging novel treatment approaches for Waldenström Macroglobulinemia
7. Response and survival predictors in a cohort of 319 patients with Waldenström macroglobulinemia treated with ibrutinib monotherapy
8. Long-term follow-up of ibrutinib monotherapy in treatment-naive patients with Waldenstrom macroglobulinemia
9. Effect of granulocyte colony-stimulating factor on toxicities after CAR T cell therapy for lymphoma and myeloma
10. Role of MBD3-SOX2 axis in residual myeloma following pomalidomide
11. Tandem high-dose influenza vaccination is associated with more durable serologic immunity in patients with plasma cell dyscrasias
12. Clinical Reasoning: Assessing New Neurologic Deficits in Patients With Hematologic Malignancy on Bruton Tyrosine Kinase Inhibitor Therapy.
13. ERK1/2 pro‐survival signalling is suppressed by pirtobrutinib in ibrutinib‐resistant MYD88‐mutated lymphoma cells.
14. Consensus treatment recommendations from the tenth International Workshop for Waldenström Macroglobulinaemia
15. Identification of robust predictors for ibrutinib response by multi-omics in MYD88 mutated Waldenstrom Macroglobulinemia
16. Lifestyle considerations in multiple myeloma
17. Clinical and Serologic Responses After a Two-dose Series of High-dose Influenza Vaccine in Plasma Cell Disorders: A Prospective, Single-arm Trial
18. Identification of robust predictors for ibrutinib response by multiomics in MYD88-mutated Waldenström macroglobulinemia
19. Report of consensus panel 5 from the 11th international workshop on Waldenstrom's macroglobulinemia on COVID-19 prophylaxis and management
20. Does Bortezomib-Dexamethasone-Rituximab-Cyclophosphamide Play a Role in the Treatment of Waldenström's Macroglobulinemia?
21. The ERK1/2 Regulator WNK2 Shows Novel Alternative Splicing Aberrations That Support Tumor Growth in MYD88 Mutated Waldenström's Macroglobulinemia
22. Identification of Robust Predictors for Ibrutinib Response By Multi-Omic Genomics in MYD88 Mutated Waldenstrom's Macroglobulinemia
23. Clinical Effectiveness and Long-Term Serologic Responses of COVID-19 Vaccination in Patients with Multiple Myeloma and Waldenström Macroglobulinemia
24. A Phase II Study of Once Weekly Carfilzomib, Lenalidomide, Dexamethasone, and Isatuximab in Newly Diagnosed, Transplant-Eligible Multiple Myeloma (The SKylaRk Trial)
25. Ibrutinib and Venetoclax in Previously Untreated Waldenström Macroglobulinemia
26. IgM-Related Immunoglobulin Light Chain (AL) Amyloidosis
27. Skin Punch Biopsy Findings in Patients with IgM MGUS and Waldenström Macroglobulinemia Presenting with Peripheral Neuropathy
28. Multi-Omic Analysis of 253 Untreated Patients with Waldenström's Macroglobulinemia Reveals Clinically and Genomically Distinct Disease Subtypes and a Model for Disease Progression
29. Quality of life, psychological distress, and prognostic perceptions in caregivers of patients with multiple myeloma
30. A new role for the SRC family kinase HCK as a driver of SYK activation in MYD88 mutated lymphomas
31. Supplement to: Clonal immunoglobulin against lysolipids in the origin of myeloma.
32. A phase II study of daratumumab with weekly carfilzomib, pomalidomide, and dexamethasone in relapsed and refractory multiple myeloma.
33. Zanubrutinib for the treatment of adults with Waldenstrom macroglobulinemia
34. Phase 1 study of ibrutinib and the CXCR4 antagonist ulocuplumab in CXCR4-mutated Waldenström macroglobulinemia
35. Quality of life, psychological distress, and prognostic perceptions in patients with multiple myeloma
36. Venetoclax in Previously Treated Waldenström Macroglobulinemia
37. Clonal Immunoglobulin against Lysolipids in the Origin of Myeloma
38. Long-term outcomes to fludarabine and rituximab in Waldenström macroglobulinemia
39. Infectious Complications in Patients Treated with Idecabtagene Vicleucel for Relapsed and Refractory Multiple Myeloma
40. A Phase II Study of Once Weekly Carfilzomib, Lenalidomide, Dexamethasone, and Isatuximab in Newly Diagnosed, Transplant-Eligible Multiple Myeloma
41. COVID-19 Vaccine Responsiveness in Patients with Multiple Myeloma and Waldenström Macroglobulinemia
42. Preliminary Clinical Response Data from a Phase 1b Study of Mavorixafor in Combination with Ibrutinib in Patients with Waldenström's Macroglobulinemia with MYD88 and CXCR4 Mutations
43. Quality of Life, Psychological Distress, and Prognostic Awareness in Patients with Multiple Myeloma
44. Quality of Life, Psychological Distress, and Prognostic Awareness in Caregivers of Patients with Multiple Myeloma
45. Pirtobrutinib (LOXO-305) Is Active and Overcomes ERK Related Pro-Survival Signaling in Ibrutinib Resistant, BTK Cys481 Mutant Expressing WM and ABC DLBCL Lymphoma Cells Driven By Activating MYD88 Mutations
46. Real-World Observations and Practical Considerations of Subcutaneous Daratumumab Administration in Multiple Myeloma
47. Molecular Features and Clinical Outcomes of Extramedullary Plasmacytomas
48. CD27-CD70 interactions in the pathogenesis of Waldenström macroglobulinemia
49. Thalidomide and rituximab in Waldenstrom macroglobulinemia
50. Long-term follow-up of ibrutinib monotherapy in treatment-naive patients with Waldenstrom macroglobulinemia
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.